Background In patients with metastatic renal cell carcinoma (mRCC), the oncologic benefit
of second-line treatment for high volume tumors or presence of more than five risk factors …

398 Background: Prior prognostic models for 2nd-line systemic therapy have not been
studied in the setting of contemporary sequential targeted therapy (TT). We sought to …

Background Two risk models, the Memorial Sloan Kettering Cancer Center (MSKCC) model
and the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) model …

Background Previous prognostic models for second-line systemic therapy in patients with
metastatic renal cell carcinoma have not been studied in the setting of targeted therapy. We …

Background: Over the past few years, significant advancements have been achieved in the
front-line treatment of metastatic renal cell carcinomas (mRCCs). However, most patients will …

4560 Background: The Heng et al JCO 2009 prognostic model was developed in the age of
VEGF-targeted therapy and this study serves as an external validation while comparing its …

339 Background: The IMDC criteria have been used as a prognostic tool for patients with
mRCC receiving single agent VEGF-targeted drugs, and more recently combination immuno …

Background Poor-risk patients with metastatic renal-cell carcinoma remain poorly
characterized in prospective clinical trials. Therefore, we sought to provide a comprehensive …

Background A novel prognostic model was recommended for patients with metastatic RCC
(mRCC) by the International mRCC Database Consortium (IMDC). In this study, we aimed to …

e15588 Background: The stratification of poor risk mRCC patients in the era of targeted
therapy represents an unmet medical need. We analyzed, individually, each prognostic …